GlassScriptPhysician profile
Jeffrey A Stevens
NPI 1659371383
$2,235.66
in general payments reported to CMS, 2019-2025
28 companies · $292 in 2025
The $292 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,085 · 2020: $230 · 2021: $188 · 2022: $40.05 · 2023: $319 · 2024: $81.83 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $617 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $617.37 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $324.33 | 2019-2025 | Opdualag, Opdivo |
| Pfizer INC. | $239.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $236.00 | 2019-2025 | Enhertu |
| Genentech USA, INC. | $186.20 | 2019-2024 | Polivy, Lunsumio, Columvi |
| Servier Pharmaceuticals LLC | $159.26 | 2021 | |
| Seagen INC. | $152.65 | 2019-2023 | Adcetris, Padcev |
| Janssen Biotech, INC. | $94.77 | 2019-2020 | |
| Daiichi Sankyo INC. | $90.16 | 2019-2025 | Enhertu |
| Gilead Sciences, INC. | $89.07 | 2019-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $73.33 | 2019-2020 | |
| Astellas Pharma US INC | $69.50 | 2019-2025 | Xtandi, Vyloy |
| Novartis Pharmaceuticals Corporation | $61.83 | 2023 | |
| Amgen INC. | $42.66 | 2020-2023 | Nplate, Xgeva, Vectibix |
| Celgene Corporation | $41.89 | 2019-2020 | |
| Lilly USA, LLC | $38.72 | 2019-2023 | Verzenio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $36.92 | 2019-2020 | |
| Exelixis INC. | $36.30 | 2019 | |
| Eisai INC. | $35.97 | 2019 | |
| Foundation Medicine, INC. | $33.86 | 2020-2023 | |
| Abbvie INC. | $33.27 | 2019 | |
| Incyte Corporation | $29.96 | 2019 | |
| Aveo Pharmaceuticals, INC. | $23.38 | 2023 | Fotivda |
| Rigel Pharmaceuticals, INC. | $22.21 | 2019 | |
| Sobi, INC | $21.77 | 2024 | |
| Genzyme Corporation | $17.12 | 2019 | |
| Dendreon Pharmaceuticals LLC | $16.86 | 2019 | |
| Taiho Oncology, INC. | $15.26 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.